Article
Cardiac & Cardiovascular Systems
Stefan H. Hohnloser, A. John Camm, Riccardo Cappato, Hans-Christoph Diener, Hein Heidbuchel, Lluis Mont, Carlos A. Morillo, Hans-Joachim Lanz, Heiko Rauer, Paul-Egbert Reimitz, Ruediger Smolnik, Josef Kautzner
Summary: This post hoc analysis of ELIMINATE-AF evaluated the requirements of unfractionated heparin (UFH) and procedure-related bleeding in atrial fibrillation (AF) patients undergoing ablation with uninterrupted edoxaban or vitamin K antagonist (VKA) therapy. The study found that despite higher doses of UFH used with edoxaban vs. VKA to achieve a target ACT during AF ablation, the rate of procedure-related major/clinically relevant non-major bleeding did not differ between the treatment arms.
Article
Medicine, General & Internal
Giuseppe Patti, Vito Maurizio Parato, Ilaria Cavallari, Paolo Calabro, Vincenzo Russo, Giulia Renda, Felice Gragnano, Vittorio Pengo, Antonio D'Onofrio, Massimo Grimaldi, Raffaele De Caterina
Summary: Edoxaban therapy in patients with atrial fibrillation and left atrial thrombus is associated with a thrombus resolution rate of over 50% at 4 weeks. Edoxaban demonstrates comparable efficacy to other oral anticoagulants in thrombus dissolution.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Medicine, General & Internal
Anna Szpotowicz, Iwona Gorczyca, Olga Jelonek, Beata Uzieblo-Zyczkowska, Malgorzata Maciorowska, Maciej Wojcik, Robert Blaszczyk, Agnieszka Kaplon-Cieslicka, Monika Gawalko, Monika Budnik, Tomasz Tokarek, Renata Rajtar-Salwa, Jacek Bil, Michal Wojewodzki, Janusz Bednarski, Elwira Bakula-Ostalska, Anna Tomaszuk-Kazberuk, Anna Szyszkowska, Marcin Welnicki, Artur Mamcarz, Malgorzata Krzciuk, Beata Wozakowska-Kaplon
Summary: Most AF patients at high risk of thromboembolic complications received OACs, but certain medical conditions may result in the lack of OAC therapy in these patients.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Medicine, General & Internal
Raffaele De Caterina, Young-Hoon Kim, Yukihiro Koretsune, Chun-Chieh Wang, Takeshi Yamashita, Cathy Chen, Paul-Egbert Reimitz, Martin Unverdorben, Paulus Kirchhof
Summary: The study found that among patients with atrial fibrillation, those treated with edoxaban had low rates of stroke, intracranial hemorrhages, and other major bleeding events, but cardiovascular death remained common.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Cardiac & Cardiovascular Systems
Elena Ivany, Deirdre A. Lane, Gheorghe-Andrei Dan, Wolfram Doehner, Michal M. Farkowski, Konstantinos Iliodromitis, Radoslaw Lenarczyk, Tatjana S. Potpara
Summary: The survey showed that the majority of doctors would prescribe oral anticoagulant therapy for patients with atrial fibrillation who have had an intracerebral haemorrhage, and would restart anticoagulant therapy more than 30 days post-ICH. The main reason for not prescribing antithrombotic therapy post-ICH was concern about recurrent intracerebral haemorrhage.
Article
Medicine, General & Internal
Tze-Fan Chao, Martin Unverdorben, Paulus Kirchhof, Yukihiro Koretsune, Takeshi Yamashita, Robert A. Crozier, Ladislav Pecen, Cathy Chen, Amanda P. Borrow, Raffaele De Caterina
Summary: Non-recommended dosing is common in non-vitamin K antagonist oral anticoagulant prescriptions, including edoxaban. Non-recommended dosing is more frequent near dose-reduction thresholds. Overdosed patients (60 mg) have lower rates of ischemic stroke and all-cause death compared to recommended 30 mg, while underdosed patients have higher all-cause death rates.
JOURNAL OF CLINICAL MEDICINE
(2023)
Editorial Material
Cardiac & Cardiovascular Systems
David Zweiker, Martin Manninger, Raphael Sieghartsleitner, Jakob Ebner, Bernadette Pratl, Egbert Bisping, Peter Lercher, Dirk von Lewinski, Rita Riedlbauer, Ursula Rohrer, Henri M. H. Spronk, Andreas Zirlik, Ulrich Schotten, Daniel Scherr
Summary: This study analyzed the impact of DOAC treatment on recurrence-free survival after AF catheter ablation, showing that despite better baseline characteristics for DOAC patients, arrhythmia-free survival was similar in both groups.
INTERNATIONAL JOURNAL OF CARDIOLOGY
(2021)
Article
Medicine, General & Internal
Giuseppe Boriani, Raffaele De Caterina, Marius Constantin Manu, Jose Souza, Ladislav Pecen, Paulus Kirchhof
Summary: This study found that patients with atrial fibrillation treated with edoxaban had low rates of stroke and bleeding regardless of weight, but extreme weight groups had a higher risk of all-cause death after adjusting for important risk modifiers. No obesity paradox was observed in this population.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Cardiac & Cardiovascular Systems
Joris J. Komen, Anton Pottegard, Aukje K. Mantel-Teeuwisse, Tomas Forslund, Paul Hjemdahl, Bjorn Wettermark, Jesper Hallas, Morten Olesen, Marion Bennie, Tanja Mueller, Raymond Carragher, Oystein Karlstad, Lars J. Kjerpeseth, Olaf H. Klungel
Summary: Observational data suggests that NOAC treatment may have a positive net clinical benefit compared with no treatment or VKA treatment in low stroke risk patients.
EUROPEAN HEART JOURNAL
(2022)
Article
Cardiac & Cardiovascular Systems
Katharina Platzbecker, Helge Mueller-Fielitz, Ronja Foraita, Matthias J. Koepp, Annemarie Voss, Rene Pflock, Roland Linder, Iris Pigeot, Tania Schink, Markus Schwaninger
Summary: This study aimed to investigate whether treatment of atrial fibrillation (AF) with direct oral anticoagulants (DOACs) affects the risk of epilepsy compared to treatment with the vitamin K antagonist phenprocoumon (PPC). The results showed that patients with AF treated with DOACs had a higher risk of epilepsy compared to PPC treatment.
Article
Medicine, General & Internal
Karim Benali, Julien Verain, Nefissa Hammache, Charles Guenancia, Darren Hooks, Isabelle Magnin-Poull, Marie Toussaint-Hacquard, Christian de Chillou, Jean-Marc Sellal
Summary: The study found that patients receiving DOAC treatment during AF ablation procedures require higher UFH doses and longer times to achieve target ACT compared to those receiving VKA treatment. Additionally, the correlation between ACT and anti-Xa activity is stronger in the VKA group. Despite lower ACT values, the DOAC group showed higher mean anti-Xa activity compared to the VKA group.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Cardiac & Cardiovascular Systems
Federico Migliore, Rui Providencia, Michal M. Farkowski, Georghe Andrei Dan, Scherr Daniel, Tatjana S. Potpara, Kristine Jubele, Julian K. R. Chun, Carlo de Asmundis, Alessandro Zorzi, Serge Boveda
Summary: The survey results showed heterogeneity in anticoagulation management before and after cardioversion in low stroke-risk patients with atrial fibrillation duration <48 hours. Periprocedural low-molecular-weight heparin was used more than non-vitamin K antagonist oral anticoagulants, and there was higher utilization of pre-cardioversion transesophageal echocardiography for electrical cardioversion than for pharmacological cardioversion.
Review
Multidisciplinary Sciences
Bailin Zhang, Winglam Cheng, Wulamiding Kaisaier, Zhenbang Gu, Wengen Zhu, Qiuhua Jiang
Summary: This meta-analysis found that edoxaban had lower risks of stroke or systemic embolism, major bleeding, and intracranial hemorrhage compared to other oral anticoagulants in patients with AF.
Article
Multidisciplinary Sciences
Rungroj Krittayaphong, Thanita Boonyapiphat, Suchart Aroonsiriwattana, Pornchai Ngamjanyaporn, Gregory Y. H. Lip
Summary: This study aimed to determine the causes of death in Asian non-valvular atrial fibrillation (AF) patients registered in a nationwide AF registry, and investigate the differences in causes of death between AF patients who were taking and not taking oral anticoagulant (OAC). The COOL-AF study in Thailand enrolled 3,405 non-valvular AF patients and found that non-cardiovascular death, such as infection/sepsis or malignancy, was more prevalent than cardiovascular death in Asian AF patients. Thus, an improved integrated care approach is needed to reduce non-cardiovascular death in Asian AF patients.
Article
Cardiac & Cardiovascular Systems
Thomas A. Zelniker, Maddalena Ardissino, Felicita Andreotti, Michelle L. O'Donoghue, Ophelia Yin, Jeong-Gun Park, Sabina A. Murphy, Christian T. Ruff, Hans J. Lanz, Elliott M. Antman, Eugene Braunwald, Robert P. Giugliano, Piera Angelica Merlini
Summary: Despite baseline differences and higher endogenous factor Xa levels in women, anticoagulation intensity with edoxaban was similar between sexes. Higher-dose edoxaban regimen showed greater reduction in hemorrhagic stroke and serious bleeding outcomes in women compared to men. Efficacy profile was similar between sexes.
Article
Cardiac & Cardiovascular Systems
Nicholas A. Marston, Giorgio E. M. Melloni, Yared Gurmu, Marc P. Bonaca, Frederick K. Kamanu, Carolina Roselli, Christina Lee, Ilaria Cavallari, Robert P. Giugliano, Benjamin M. Scirica, Deepak L. Bhatt, Philippe Gabriel Steg, Marc Cohen, Robert F. Storey, Anthony C. Keech, Itamar Raz, Ofri Mosenzon, Eugene Braunwald, Steven A. Lubitz, Patrick T. Ellinor, Marc S. Sabatine, Christian T. Ruff
Summary: The study tested a genetic risk score for predicting venous thromboembolism in patients with cardiometabolic disease. Results showed that the genetic risk score was significantly associated with VTE risk, and could independently predict the occurrence of VTE in this patient population.
CIRCULATION-GENOMIC AND PRECISION MEDICINE
(2021)
Article
Cardiac & Cardiovascular Systems
Emily S. Lau, Eugene Braunwald, David A. Morrow, Robert P. Giugliano, Elliott M. Antman, C. Michael Gibson, Benjamin M. Scirica, Erin A. Bohula, Stephen D. Wiviott, Deepak L. Bhatt, Marc P. Bonaca, Christopher P. Cannon, KyungAh Im, Jianping Guo, Marc S. Sabatine, Michelle L. O'Donoghue
Summary: This study found that women were more likely than men to prematurely discontinue study drug and withdraw consent in cardiovascular outcome trials. Despite adjusting for baseline differences, this difference still existed, indicating potential barriers to continued study drug use and clinical trial participation, particularly among women.
Article
Cardiac & Cardiovascular Systems
Nicholas A. Marston, Parth N. Patel, Frederick K. Kamanu, Francesco Nordio, Giorgio M. Melloni, Carolina Roselli, Yared Gurmu, Lu-Chen Weng, Marc P. Bonaca, Robert P. Giugliano, Benjamin M. Scirica, Michelle L. O'Donoghue, Christopher P. Cannon, Christopher D. Anderson, Deepak L. Bhatt, Philippe Gabriel Steg, Marc Cohen, Robert F. Storey, Peter Sever, Anthony C. Keech, Itamar Raz, Ofri Mosenzon, Elliott M. Antman, Eugene Braunwald, Patrick T. Ellinor, Steven A. Lubitz, Marc S. Sabatine, Christian T. Ruff
Summary: Genome-wide association studies have identified single-nucleotide polymorphisms associated with an increased risk of stroke. A genetic risk score (GRS) using 32 single-nucleotide polymorphisms was found to be a strong, independent predictor of ischemic stroke across a broad spectrum of subjects with cardiometabolic disease. In patients with atrial fibrillation and lower CHA(2)DS(2)-VASc scores, the GRS identified patients with a risk level comparable to those with higher scores.
Letter
Public, Environmental & Occupational Health
Robert P. Giugliano, Raffaele De Caterina, Takeshi Yamashita
Article
Cardiac & Cardiovascular Systems
Anthony P. Carnicelli, Hwanhee Hong, Stuart J. Connolly, John Eikelboom, Robert P. Giugliano, David A. Morrow, Manesh R. Patel, Lars Wallentin, John H. Alexander, M. Cecilia Bahit, Alexander P. Benz, Erin A. Bohula, Tze-Fan Chao, Leanne Dyal, Michael Ezekowitz, Keith A.a. Fox, Baris Gencer, Jonathan L. Halperin, Ziad Hijazi, Stefan H. Hohnloser, Kaiyuan Hua, Elaine Hylek, Eri Toda Kato, Julia Kuder, Renato D. Lopes, Kenneth W. Mahaffey, Jonas Oldgren, Jonathan P. Piccini, Christian T. Ruff, Jan Steffel, Daniel Wojdyla, Christopher B. Granger
Summary: DOACs have more favorable efficacy and safety profiles compared to warfarin in patients with atrial fibrillation, showing significant advantages in terms of stroke, systemic embolism, and bleeding.
Article
Cardiac & Cardiovascular Systems
Christopher B. Fordyce, Robert P. Giugliano, Christopher P. Cannon, Matthew T. Roe, Abhinav Sharma, Courtney Page, Jennifer A. White, Yuliya Lokhnygina, Eugene Braunwald, Michael A. Blazing
Summary: This study examines the long-term incidence and influence of cardiovascular events before sudden death among stabilized patients after an acute coronary syndrome (ACS). The results show that patients stabilized within 10 days of ACS remain at long-term risk of sudden death, with the greatest risk in those with an additional cardiovascular event.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2022)
Article
Cardiac & Cardiovascular Systems
Joseph Edgar Blais, Yue Wei, Martin Knapp, Ian C. K. Wong, Li Wei, Esther W. Chan
Summary: This study aims to describe trends in PCSK9 inhibitor adoption and utilization between 2015 and 2019 in the United States, Europe, and other countries.
AMERICAN HEART JOURNAL
(2022)
Article
Cardiac & Cardiovascular Systems
Dylan L. Steen, Irfan Khan, Katherine Andrade, Alexandra Koumas, Robert P. Giugliano
Summary: Patients with acute coronary syndrome (ACS) remain at a very high risk of experiencing recurrent cardiovascular events, particularly early after discharge. Among different subgroups, patients without revascularization and with a Thrombolysis In Myocardial Infarction Risk Score for Secondary Prevention >= 4 had the highest 5-year event rate for the primary cardiovascular end point.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2022)
Article
Cardiac & Cardiovascular Systems
Michelle L. O'Donoghue, Robert P. Giugliano, Stephen D. Wiviott, Dan Atar, Anthony Keech, Julia F. Kuder, KyungAh Im, Sabina A. Murphy, Jose H. Flores-Arredondo, J. Antonio G. Lopez, Mary Elliott-Davey, Bei Wang, Maria Laura Monsalvo, Siddique Abbasi, Marc S. Sabatine
Summary: Long-term use of evolocumab to lower LDL-C levels is associated with low rates of adverse events, which do not exceed those in the placebo group. Over time, the use of evolocumab also leads to further reduction in cardiovascular events.
Editorial Material
Cardiac & Cardiovascular Systems
Alda Huqi, Carmine Zoccali, Robert P. Giugliano, Raffaele De Caterina
EUROPEAN HEART JOURNAL
(2023)
Letter
Cardiac & Cardiovascular Systems
Michelle L. O'Donoghue, Robert P. Giugliano, Marc S. Sabatine
Article
Cardiac & Cardiovascular Systems
Josephine Harrington, Anthony P. Carnicelli, Kaiyuan Hua, Lars Wallentin, Manesh R. Patel, Stefan H. Hohnloser, Robert P. Giugliano, Keith A. A. Fox, Ziad Hijazi, Renato D. Lopes, Sean D. Pokorney, Hwanhee Hong, Christopher B. Granger
Summary: Through meta-analysis of multiple research databases, it was found that standard-dose DOACs are safer and more effective than warfarin in patients with kidney dysfunction. While lower-dose DOACs do not significantly lower the incidence of bleeding or intracranial hemorrhage compared to standard-dose DOACs, they are associated with a higher incidence of stroke and systemic embolism as well as death. Therefore, these findings support the use of standard-dose DOACs over warfarin in patients with kidney dysfunction.
Article
Cardiac & Cardiovascular Systems
Alexander P. Benz, Stefan H. Hohnloser, John W. Eikelboom, Anthony P. Carnicelli, Robert P. Giugliano, Christopher B. Granger, Josephine Harrington, Ziad Hijazi, David A. Morrow, Manesh R. Patel, David J. Seiffge, Ashkan Shoamanesh, Lars Wallentin, Qilong Yi, Stuart J. Connolly
Summary: This study aimed to investigate the prognosis of patients with atrial fibrillation (AF) and ischemic stroke while on oral anticoagulation. The results showed that among the 1163 patients who had a post-randomization ischemic stroke while on study medication, 7.0% had a recurrent ischemic stroke within 1 year, and the all-cause mortality rate within 3 months was 12.4%.
EUROPEAN HEART JOURNAL
(2023)
Letter
Cardiac & Cardiovascular Systems
Nishant P. Shah, Darren K. McGuire, Christopher P. Cannon, Robert P. Giugliano, Yuliya Lokhnygina, Courtney B. Page, Andrew M. Tershakovec, Eugene Braunwald, Michael A. Blazing
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2023)
Review
Urology & Nephrology
Carmine Zoccali, Francesca Mallamaci, Michel Halimi, Patrick Rossignol, Pantelis Serafidis, Raffaele De Caterina, Robert Giugliano, Faiez Zannad
Summary: This review discusses the problems with the current classification of cardio renal syndrome, proposing the term chronic cardiovascular-kidney disorder (CCKD) instead. It highlights the shared risk factors and pathophysiological mechanisms between cardiovascular and chronic kidney disease (CKD), as well as the potential for treatments targeting both conditions to improve outcomes.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
(2023)